

Lumito receives order from Swedish research unit

Lumito AB (publ) ("Lumito" or the "Company") today announces that the Company has received an order for a SCIZYS Erbium kit from a research unit in Sweden. The customer will utilise the Company's Scan-as-a-Service offering.

The Company has received an order at an initial value of 10-20 kSEK from an organisation that has experienced limitations with established analytical methods, including disruptive tissue autofluorescence and limited sensitivity in the detection of biomarkers. Against this background, the customer intends to use Lumito's SCIZYS product to enable measurement of low levels of biomarkers in tissue samples, as well as to achieve an efficient and simplified workflow.

"Although the order value at this stage is limited, we view the transaction as an important step in Lumito's commercial development and a confirmation that we are doing the right things. Our Scan-as-a-Service offering lowers the threshold for customers to start using our technology and creates conditions for long-term relationships and recurring revenue. The order confirms both our product and our business model and provides us with valuable experience ahead of continued commercialisation", säger Sanna Wallenborg, VD för Lumito.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Lumito receives order from Swedish research unit](#)